Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LUMIGAN

« Back to Dashboard
Lumigan is a drug marketed by Allergan and is included in two NDAs. It is available from two suppliers. There are nine patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in LUMIGAN is bimatoprost. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the bimatoprost profile page.

Summary for Tradename: LUMIGAN

Suppliers: see list2

Pharmacology for Tradename: LUMIGAN

Drug ClassProstaglandin Analog

Clinical Trials for: LUMIGAN

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
Status: Completed Condition: Hypertrichosis

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Status: Completed Condition: Glaucoma, Open-Angle; Ocular Hypertension

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Status: Recruiting Condition: Primary Open Angle Glaucoma; Ocular Hypertension

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
Status: Completed Condition: Alopecia Areata

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
Status: Completed Condition: Glaucoma; Ocular Hypertension

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
Status: Active, not recruiting Condition: Glaucoma; Periocular Skin Pigmentation Changes

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US
Status: Completed Condition: Glaucoma; Ocular Hypertension

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®
Status: Completed Condition: Glaucoma; Ocular Hypertension

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
Status: Completed Condition: Glaucoma; Ocular Hypertension; Open-Angle Glaucoma

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Status: Active, not recruiting Condition: Glaucoma; Ocular Hypertension

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
SOLUTION/DROPS;OPHTHALMIC022184Aug 31, 2010RXYes8,772,338<disabled>Y<disabled>
SOLUTION/DROPS;OPHTHALMIC022184Aug 31, 2010RXYes5,688,819<disabled><disabled>
SOLUTION/DROPS;OPHTHALMIC021275Mar 16, 2001DISCNNo5,688,819<disabled><disabled>
SOLUTION/DROPS;OPHTHALMIC022184Aug 31, 2010RXYes8,586,630<disabled><disabled>
SOLUTION/DROPS;OPHTHALMIC022184Aug 31, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LUMIGAN

Drugname Dosage Strength RLD Submissiondate
bimatoprostOphthalmic Solution0.01%Lumigan4/5/2011
bimatoprostOphthalmic Solution0.03%Lumigan12/22/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn